Hepatitis b vaccine (recombinant), adjuvanted - Biologic Drug Details

Summary for hepatitis b vaccine (recombinant), adjuvanted

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2

Pharmacology for hepatitis b vaccine (recombinant), adjuvanted

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Hepatitis B Virus Vaccine
Chemical Structure	Hepatitis B Vaccines Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for hepatitis b vaccine (recombinant), adjuvanted Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for hepatitis b vaccine (recombinant), adjuvanted Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Dynavax Technologies Corporation	HEPLISAV-B	hepatitis b vaccine (recombinant), adjuvanted	Injection	125428	10,314,907	2038-01-18	DrugPatentWatch analysis and company disclosures
Dynavax Technologies Corporation	HEPLISAV-B	hepatitis b vaccine (recombinant), adjuvanted	Injection	125428	9,452,212	2032-04-16	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for hepatitis b vaccine (recombinant), adjuvanted Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

Hepatitis b vaccine (recombinant), adjuvanted Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Current Market Dynamics for the Recombinant Hepatitis B Vaccine (Adjuvanted)?

The global hepatitis B vaccine market, specifically recombinant and adjuvanted formulations, is driven by increasing vaccination rates, expanding immunization programs, and advancements in vaccine technology. The compound annual growth rate (CAGR) for this segment is projected at approximately 7% through 2030, reaching an estimated market value of $4.2 billion by 2030, up from $1.9 billion in 2022 (MarketsandMarkets). Growth factors include:

• The expanding global incidence of hepatitis B, with an estimated 296 million chronic infections, primarily in Africa and Asia (WHO, 2022).
• The introduction of adjuvants like AS04 to improve immunogenicity, especially in vulnerable populations.
• Vaccination mandates and policy implementations in low- and middle-income countries (LMICs), driven by WHO immunization goals.
• Patent expirations for certain formulations, opening niche markets and potential generic or biosimilar entries.
• The COVID-19 pandemic shifting focus toward immunization infrastructure, which could benefit hepatitis B vaccination programs.

How Does the Product Profile of Recombinant and Adjuvanted Hepatitis B Vaccine Influence Market Adoption?

Recombinant hepatitis B vaccines were first introduced in the 1980s and have become standard due to safety and cost-effectiveness compared to plasma-derived vaccines. The adjuvanted versions, notably containing adjuvants like AS04, demonstrate improved immune response, especially in:

• Neonates and elderly populations, where enhanced immunogenicity is critical.
• Immunocompromised individuals, including HIV-positive groups.
• Regions with high hepatitis B endemicity.

The inclusion of adjuvants extends the vaccine's efficacy and reduces the number of doses required, influencing purchasing decisions by governments and healthcare providers. The vaccines' thermostability and ease of integration into existing immunization schemes further promote availability.

What Are the Key Competitive and Regulatory Factors Shaping the Market?

Major pharmaceutical companies such as GlaxoSmithKline (GSK), Merck, and PVN Holdings dominate the market. GSK’s FENDrix vaccine, adjuvanted with AS04, is notable for its enhanced immunogenicity. Regulatory agencies like the FDA and EMA require rigorous clinical data to approve adjuvanted vaccines, emphasizing safety and efficacy. Market entry barriers include:

• Lengthy development timelines (minimum 5-7 years for new formulations).
• High costs of large-scale production and clinical trials.
• Stringent regulatory pathways, especially for adjuvanted vaccines due to safety concerns related to adjuvant components.

The emergence of biosimilars or generic recombinant vaccines faces regulatory challenges due to patent protections and complex manufacturing processes.

What Are the Financial Trajectories and Investment Trends?

The revenue from the hepatitis B vaccine market is projected to grow steadily. In 2022, the market generated approximately $1.9 billion, with key contributors being vaccination programs in Africa, Asia, and Latin America. Major trends include:

• Increased procurement by GAVI Alliance and UNICEF, accounting for roughly 40% of global vaccine distribution (GAVI, 2022).
• Emerging markets adopting expanded immunization schedules, including booster and adolescent vaccination.
• Crests in R&D investments to develop next-generation vaccines with broader coverage and fewer doses.

Funding for R&D involving adjuvants is rising, with an annual increase of about 10%. The focus is on innovative adjuvant systems, thermostability, and delivery modalities like needle-free injectors.

How Does Market Competition & Patent Environment Influence Future Growth?

Patent expirations for early recombinant vaccines, expected around 2025-2027, could enable generic manufacturers to enter markets at lower prices, especially in LMICs. Conversely, patent protections for novel adjuvanted formulations can delay generic penetration but might reward innovation with higher prices in high-income markets until patent expiry.

Market dominance by established players and supplier agreements with organizations like GAVI support stable revenue streams. Patent disputes or challenges over adjuvant safety data could influence the competitive landscape.

What Are the Regulatory and Policy Trends Impacting Future Trajectory?

Global efforts to eradicate hepatitis B by 2030 are intensifying. WHO’s guidelines recommend universal infant vaccination and booster doses where appropriate. Vaccine approval pathways for new adjuvanted products are becoming streamlined but still demand comprehensive safety data.

Post-market surveillance and safety concerns about adjuvants (e.g., rare adverse events like injection site reactions or hypersensitivity) influence regulatory scrutiny. Governments prioritize vaccines with proven safety profiles, affecting market access strategies.

Key Takeaways

• The hepatitis B vaccine market is expanding, driven by product innovation, immunization policies, and increased demand in endemic regions.
• Recombinant vaccines, especially adjuvanted variants containing adjuvants like AS04, provide higher immunogenicity, influencing coverage policies.
• Major players own dominant market share, with patent protections and regulatory pathways shaping competition.
• The market is forecasted to reach $4.2 billion by 2030, with sustained growth in low- and middle-income countries.
• R&D investment focus on improved adjuvants and delivery systems aims to enhance vaccine efficacy and acceptance.

FAQs

1. How do adjuvants improve hepatitis B vaccine efficacy?
Adjuvants like AS04 enhance the immune response by stimulating innate immunity, allowing for fewer doses and improved protection, especially in populations with weaker immune systems.

2. What regions are experiencing the fastest growth in hepatitis B vaccination?
Africa, Southeast Asia, and parts of Latin America are experiencing rapid growth due to high hepatitis B prevalence and expanding immunization programs.

3. When are biosimilars expected to enter the market?
Biosimilars for recombinant hepatitis B vaccines are anticipated around 2025-2027, after patent protections expire or are challenged.

4. What are the primary safety concerns regarding adjuvanted hepatitis B vaccines?
Concerns focus on rare adverse events like hypersensitivity or injection site reactions, but existing data affirm safety profiles when used as approved.

5. How has COVID-19 affected hepatitis B vaccine market dynamics?
The pandemic led to increased attention on vaccination infrastructure, potentially boosting immunization programs, while supply chain disruptions caused temporary delays in vaccine distribution.

---

Citations

[1] MarketsandMarkets. "Hepatitis B Vaccines Market." 2022.
[2] WHO. "Hepatitis B Fact Sheet." 2022.
[3] GAVI. "Vaccine procurement reports." 2022.
[4] FDA. "Guidance for Industry: Clinical Data Needed to Support the Licensure of Hepatitis B Vaccines." 2021.